Literature DB >> 10748154

Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL.

J L Bodmer1, P Meier, J Tschopp, P Schneider.   

Abstract

Unlike other tumor necrosis factor family members, the cytotoxic ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L contains an unpaired cysteine residue (Cys(230)) in its receptor-binding domain. Here we show that the biological activity of both soluble recombinant TRAIL and cell-associated, full-length TRAIL is critically dependent on the presence of Cys(230). Mutation of Cys(230) to alanine or serine strongly affected its ability to kill target cells. Binding to its receptors was decreased by at least 200-fold, and the stability of its trimeric structure was reduced. In recombinant TRAIL, Cys(230) was found engaged either in interchain disulfide bridge formation, resulting in poorly active TRAIL, or in the chelation of one zinc atom per TRAIL trimer in the active, pro-apoptotic form of TRAIL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10748154     DOI: 10.1074/jbc.M909721199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

2.  Leachables from saline-containing IV bags can alter therapeutic protein properties.

Authors:  Judy Y Chang; Nina J Xiao; Min Zhu; Jennifer Zhang; Ed Hoff; Stephen J Russell; Viswanatham Katta; Steven J Shire
Journal:  Pharm Res       Date:  2010-06-30       Impact factor: 4.200

Review 3.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

4.  Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.

Authors:  Fatma Aboulnasr; Ashton Krogman; Rondell P Graham; Nathan W Cummins; Anisha Misra; Enrique Garcia-Rivera; Jeff R Anderson; Sekar Natesampillai; Nicole Kogan; Murali Aravamudan; Zilin Nie; Thomas D Y Chung; Richard Buick; Andrew L Feldman; Rebecca L King; Anne J Novak; Stephen M Ansell; Saad Kenderian; Andrew D Badley
Journal:  Clin Cancer Res       Date:  2020-07-15       Impact factor: 12.531

5.  Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.

Authors:  Keli Song; Nordine Benhaga; Robin L Anderson; Roya Khosravi-Far
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

6.  A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing.

Authors:  Dirk Spitzer; Jonathan E McDunn; Stacey Plambeck-Suess; Peter S Goedegebuure; Richard S Hotchkiss; William G Hawkins
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

7.  The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors:  Brett D Shepard; Andrew D Badley
Journal:  Antiinfect Agents Med Chem       Date:  2009-04-01

8.  Primary immune effects of eukaryotic expression plasmids encoding two hyperactive mutants of human soluble B lymphocyte stimulator.

Authors:  Guangyu Chen; Hongwu Du; Zhengjian Zhang; Shanyun Peng; Donggang Xu; Jiaxi Wang
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

Review 9.  Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; William M Nauseef; Thomas S Griffith
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells.

Authors:  Kerstin Reimers; Christine Radtke; Claudia Y Choi; Christina Allmeling; Susanne Kall; Paul Kiefer; Thomas Muehlberger; Peter M Vogt
Journal:  Ann Surg Innov Res       Date:  2009-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.